Skip to main content

Analysts Offer Insights on Financial Companies: OneMain Holdings (OMF) and OCBC (OtherOVCHF)

Tipranks - Wed Jan 28, 10:24AM CST

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on OneMain Holdings (OMFResearch Report) and OCBC (OVCHFResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

OneMain Holdings (OMF)

Northland Securities analyst Michael Grondahl maintained a Buy rating on OneMain Holdings today and set a price target of $68.00. The company’s shares closed last Tuesday at $64.91.

According to TipRanks.com, Grondahl is a 5-star analyst with an average return of 13.4% and a 45.8% success rate. Grondahl covers the Financial sector, focusing on stocks such as HIVE Digital Technologies, Abacus Global Management, and Riot Platforms. ;'>

Currently, the analyst consensus on OneMain Holdings is a Moderate Buy with an average price target of $72.60, which is a 10.8% upside from current levels. In a report issued on January 14, TD Cowen also maintained a Buy rating on the stock with a $80.00 price target.

See the top stocks recommended by analysts >>

OCBC (OVCHF)

In a report released yesterday, Wee Kuang Tay from CGS International maintained a Buy rating on OCBC, with a price target of S$23.40. The company’s shares closed last Monday at $16.68.

According to TipRanks.com, Tay is ranked #4838 out of 12040 analysts.

Currently, the analyst consensus on OCBC is a Strong Buy with an average price target of $16.87, a 1.8% upside from current levels. In a report issued on January 19, TipRanks – Google also upgraded the stock to Buy with a S$22.50 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.